Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.1052W HIGH $4.00
Volume
271.32 K
Value Traded
243.54 K
Short % Float
5.55%
-7.75%Week
-6.02%1 Month
+2.04%3 Month
-24.24%6 Month
-55.99%5 Year
-79.94%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
254.43 M
EPS (TTM)
-0.82
P/E Ratio
-
Ent. Value
158.57 M
Total Shares
101.73 M
Float Shares
62.57 M
Insiders
38.52%
Institutions
24.30%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ACIU Catalyst Timeline
Dated clinical, regulatory and corporate events for AC Immune SA
Catalyst Timeline
Dated clinical, regulatory & corporate events for AC Immune SA
505Total events
15Upcoming
146Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Primary Endpoint MetACI-7104FiledClinical Data
All primary endpoints met in Part 1 of VacSYn Phase 2 trial of ACI-7104
early-stage Parkinson's diseasesource ↗
▲Safety Data UpdateACI-7104FiledClinical Data
Positive safety and immunogenicity results through week-100 in Part 1 of VacSYn
early-stage Parkinson's diseasesource ↗
▲Biomarker DataACI-7104FiledClinical Data
Exploratory biomarker analyses show signal for total a-syn in CSF
early-stage Parkinson's diseasesource ↗
▲Topline ReadoutACI-19764Clinical Data
Positive preliminary Phase 1 data for ACI-19764
NLRP3 inflammasome-related diseasessource ↗
▲Enrollment UpdateACI-19764Trial
Dosing of cardiovascular risk cohort initiated
cardiovascular risk with elevated hsCRP and type 2 diabetes and/or obesitysource ↗
▲Fast Track DesignationACI-7104FiledDesignation
FDA grants Fast Track designation for ACI-7104
Early Parkinson’s Disease (PD)source ↗
▲IND ClearanceACI-7104FiledIND
IND clearance for ACI-7104 to expand VacSYn study to US sites
Early Parkinson’s Disease (PD)source ↗
▲Interim AnalysisACI-7104FiledTrial
Positive interim results from VacSYn study
Early Parkinson’s Disease (PD)source ↗
▲Milestone PaymentACI-24 low doseCorporate
Received $12 million milestone payment from Takeda
Prodromal Alzheimer's diseasesource ↗
▲First Patient DosedACI-24 low doseTrial
Dosed first patients in Cohort AD4 of ABATE trial
Prodromal Alzheimer's diseasesource ↗
▲Interim AnalysisACI-24 low doseTrial
Reported high level interim data from AD1, AD2, AD3 cohorts
Prodromal Alzheimer's diseasesource ↗
▲Partnership / LicenseMorphomer-TauCorporate
Amended agreement with Lilly to include new lead Tau Morphomer candidates
Tauopathiessource ↗
▲Milestone PaymentMorphomer-TauCorporate
Received CHF10 million upfront payment from Lilly
Tauopathiessource ↗
●Management ChangeCorporate
Dr Andrea Pfeifer retired as CEO; Dr Martin Zügel appointed interim CEO
▲NDA SubmissionACI-7104FiledRegulatory Filing
Received $4 million grant from Goradia Charitable Foundation
Parkinson's diseasesource ↗
▲Oral PresentationACI-19626Presentation
Presented preliminary results from Phase 1 trial of ACI-19626
Amyotrophic lateral sclerosissource ↗
▲Interim AnalysisACI-7104FiledTrial
Previously reported interim results from Part 1 at 76 weeks
Parkinson's diseasesource ↗
◆Topline ReadoutACI-19764Clinical Data
Initial SAD/MAD and pharmacodynamics results expected in near future
Healthy volunteerssource ↗
◆Topline ReadoutACI-24 low doseClinical Data
Interim 12-month data from first three AD cohorts (AD1, AD2, AD3)
prodromal Alzheimer's diseasesource ↗
▲Enrollment CompleteACI-24 low doseTrial
Recruitment concluded for DS3 cohort
Down syndrome with Alzheimer's diseasesource ↗
▲First Patient DosedACI-24 low doseTrial
First patients dosed in ABATE Cohort AD4
prodromal Alzheimer's diseasesource ↗
▲Milestone PaymentACI-24 low doseCorporate
$12 million milestone payment from Takeda on dosing of first patients in Cohort AD4
▲Trial InitiationACI-24 low doseTrial
Initiation of Cohort AD4 evaluating ACI-24 with additional adjuvant
prodromal Alzheimer's diseasesource ↗
▲Partnership / LicenseCorporate
Research grant of $4 million from Goradia Family Foundation to support extension of Part 1 of Phase 2 VacSYn trial of ACI-7104
◆Full ResultsACI-7104.056Clinical Data
Final data from Part 1 of VacSYn trial expected mid-2026
Parkinson's diseasesource ↗
▲Oral PresentationACI-19626Presentation
Presentation of new Phase 1 data for ACI-19626 at 2026 TDP43 Summit showing higher uptake in ALS patients
amyotrophic lateral sclerosis (ALS)source ↗
▲Trial InitiationACI-19626Trial
Part 2 expansion of Phase 1 trial started, may include up to 30 patients with FTD, ALS or LATE
frontotemporal dementia (FTD), ALS, LATEsource ↗
▲Primary CompletionACI-19626Trial
Part 1 of Phase 1 trial in healthy volunteers and genetic FTD patients completed
genetic frontotemporal dementia (FTD)source ↗
▲First Patient DosedACI-24 low doseTrial
First patients dosed in Cohort AD4 of ABATE trial
Alzheimer's diseasesource ↗
▲Milestone PaymentCorporate
$12 million milestone payment from Takeda for dosing first patients in Cohort AD4
▲Milestone PaymentACI-24 low doseCorporate
$12 million milestone payment from Takeda triggered by first patient in cohort AD4
Alzheimer's Diseasesource ↗
▲First Patient DosedACI-19764Trial
First subjects dosed in Phase 1 trial of ACI-19764
Neurodegenerative diseasessource ↗
▲Oral PresentationACI-7104FiledPresentation
Presented updated interim results from Part 1 of Phase 2 VacSYn trial at AD/PD 2026
Parkinson's diseasesource ↗
▲Enrollment MilestoneACI-24 low doseTrial
Initiated final cohort AD4 in ABATE trial of ACI-24
Alzheimer's Diseasesource ↗
▲Partnership / LicenseMorphomer-TauCorporate
Amended Morphomer Tau collaboration with Lilly
Alzheimer's Diseasesource ↗
▲Oral PresentationACI-19626Presentation
Presented Phase 1 data including first in vivo images of TDP-43 pathology at AD/PD 2026
Frontotemporal dementiasource ↗
●Protocol AmendmentACI-35.030Trial
Protocol amendment for ReTain study being sought by Janssen
Alzheimer's Diseasesource ↗
▲Partnership / LicenseCorporate
Amendment to Morphomer Tau License and Collaboration Agreement with Lilly
◆IND Enabling CompletePreclinical
IND-enabling studies expected to initiate imminently
Alzheimer's disease and other neurodegenerative diseasessource ↗
◆Topline ReadoutACI-24 low doseClinical Data
12-month data from Cohorts AD1, AD2, AD3 expected
Alzheimer's diseasesource ↗
◆Full ResultsACI-7104.056Clinical Data
Final data from Part 1 of VacSYn trial expected
Parkinson's diseasesource ↗
◆Full ResultsACI-7104FiledClinical Data
Final data from Part 1 of Phase 2 VacSYn trial of ACI-7104 expected in mid-2026
Parkinson's diseasesource ↗
◆Oral PresentationACI-19626Presentation
Oral presentation on discovery and initial clinical evaluation of [18f]ACI-19626, a first-in-class TDP-43 PET-tracer at AD/PD 2026
Neurodegenerative diseases (TDP-43 proteinopathies)source ↗
Past FDA Catalysts and PDUFA Decisions
How ACIU actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-12 | ACI-19764 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C43 / 100
Pipeline Score
$88M
Pipeline Value
Overvalued
Valuation Signal
6
Drugs Scored
0.3x
rNPV / MCap
Top 30%
Micro Cap(rank 198 of 657)
Percentile Rank
AC Immune SA carries a moderate pipeline score (43/100), with $903M risk-adjusted pipeline value, led by ACI-19764 in Obesity (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ACI-19764 Small moleculeNCT07463196 | Obesity | Phase 1 | RECRUITING | 114 | Dec 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ACIU program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ACI-7104 Fast Track | early-stage Parkinson's disease | Phase 2 | 2026-09-23 | 100% response rate after three immunizations; 34 patients randomized into the study (25 patients receiving ACI-7104 and nine receiving placebo); 100% of patients developing antibodies against the immunizing a-syn target antigen PD01 after three immunizationsRead More | AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pfeifer AndreaDirector, Officer (Chief Executive Officer) | Sell | -10,000 3,820,288 held | $2.79 | 05/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ACIU
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 1.2 % (-29.4 %) | 47.18 M | 19.82 M |
ACIU Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ACIU ranks across every disease it competes in
Competitive Position is a premium feature
See how ACIU ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialACIU News
ACIUAC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
AC Immune announced positive results from Part 1 of the VacSYn Phase 2 trial for ACI-7104, showing safety, tolerability, and strong immunogenicity in patients with early-stage Parkinson's disease. The trial met all primary endpoints, with a 100% response rate observed after three immunizations. The company plans to discuss future development steps with the FDA in early 2027.
Read more →ACIUAC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
AC Immune announced positive preliminary results from a Phase 1 trial of ACI-19764, an oral NLRP3 inflammasome inhibitor. The drug demonstrated safety and tolerability across dosing cohorts, with evidence of brain penetration. The trial is now expanding to include patients with cardiovascular disease risk, with further results anticipated in early 2027.
Read more →ACIU▲ +11.4%on this news
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
AC Immune has received FDA Fast Track Designation for its anti-alpha-synuclein immunotherapy, ACI-7104, aimed at treating early Parkinson's Disease. The company plans to expand its ongoing Phase 2 VacSYn study to additional sites in the USA following Investigational New Drug clearance. Recent interim results have shown promising safety outcomes.
Read more →ACIUAC Immune First Half 2026 Financial and Corporate Update
AC Immune provided a financial and corporate update for the first half of 2026, highlighting advancements in its clinical pipeline, including the Phase 2 VacSYn trial for Parkinson's disease and the initiation of the AD4 cohort in the ABATE trial for Alzheimer's disease. The company reported a cash position of CHF 75.4 million, sufficient to fund operations into Q4 2027. Despite a net loss of CHF 12.9 million, milestone payments from partnerships are supporting ongoing development.
Read more →ACIUAC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
AC Immune SA will present three key studies at the Alzheimer's Association International Conference 2026, highlighting advancements in neurodegenerative disease therapies. The presentations will showcase a TDP-43 PET tracer, a brain-penetrant NLRP3 inhibitor in Phase 1, and an aggregation inhibitor targeting alpha-synuclein pathology. These developments underscore the company's commitment to innovative treatments for conditions like Alzheimer's and Parkinson's diseases.
Read more →ACIU▼ -10.5%on this news
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
AC Immune announced interim results from the Phase 1b/2 ABATE trial of ACI-24 in patients with prodromal Alzheimer's disease. The treatment was found to be generally safe, with no evidence of amyloid-related imaging abnormalities. A dose-response relationship for anti-Abeta antibodies was observed, and a new cohort is being tested with an additional adjuvant to enhance immunogenicity.
Read more →ACIU▲ +6.6%on this news
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
AC Immune has secured a $4 million research grant from the Goradia Family to extend Part 1 of the Phase 2 VacSYn trial for ACI-7104, targeting early Parkinson's disease. This funding will allow for an additional two years of study to assess long-term safety and efficacy. Interim results have shown promise, indicating potential disease-modifying effects.
Read more →ACIU▲ +6.6%on this newsshared move
NASDAQ: ACIU | AGM Presentation
AC Immune presented updates at its Annual General Meeting on June 11, 2026, highlighting its innovative approaches to neurodegenerative diseases through active immunotherapy. The company reported a robust cash reserve that provides financial stability until Q4 2027 and shared positive results from ongoing clinical trials. However, it also cautioned about inherent risks and uncertainties tied to its forward-looking statements and operations affected by COVID-19. AC Immune aims to lead in precision prevention and treatment in the neurodegenerative space with its promising pipeline.
Read more →ACIU▲ +6.6%on this newsshared move
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease
AC Immune SA has received a $4 million research grant from the Vijay and Marie Goradia Charitable Foundation to support the continued development of ACI-7104 in early Parkinson's disease. This funding will facilitate the extension of Part 1 of the Phase 2 VacSYn trial, following positive interim results that indicated the compound could have a disease-modifying effect. The grant aims to generate crucial data to aid the treatment of patients at the early stages of this neurodegenerative condition. AC Immune's CEO expressed gratitude for the grant, highlighting the company's commitment to precision prevention in neurodegenerative diseases.
Read more →ACIUAC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
AC Immune presented new Phase 1 data at the 2026 TDP43 Summit, showing that its PET tracer ACI-19626 has significantly higher uptake in ALS patients compared to healthy controls. The findings suggest the tracer's potential for early diagnosis and intervention in neurodegenerative diseases. The ongoing trial continues to demonstrate a favorable safety profile.
Read more →ACIUto the Company's Form 6 - K on 13 March 2026 can be downloaded from the Company's website at ir.acimmune.com/events/agm . It explains the governance framework and the principles underlying the compensation structure at A
AC Immune has made notable advancements in its clinical pipeline, especially with ACI-7104 showing promise in treating Parkinson's disease. The company has reported good safety data and positive immunogenicity in key trials, affirming their strategy for precision prevention of neurodegenerative diseases. While they face challenges, including a paused recruitment for one trial and workforce reductions, their ongoing investment in research and collaborations indicates strong potential for future success. AC Immune will be focusing on class-leading products to treat and prevent neurodegenerative diseases moving forward.
Read more →ACIUAC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
AC Immune's CEO, Dr. Andrea Pfeifer, will retire at the upcoming AGM after 23 years. Martin Zügel, the Board Chair, will take over as interim CEO while a search for a permanent successor is conducted. Dr. Pfeifer will continue to support the company as an Advisor and Honorary Chair. The company remains strong with a promising pipeline and strategic partnerships.
Read more →ACIUAC Immune First Quarter 2026 Financial and Corporate Updates
AC Immune reported financial and corporate updates for Q1 2026, highlighting the initiation of a Phase 1 trial for ACI-19764 and the final cohort in the ABATE trial for ACI-24. The company amended its collaboration with Eli Lilly, reflecting progress in targeting Tau proteins. Despite a net loss of CHF 14.8 million, AC Immune's cash resources are projected to sustain operations through Q4 2027.
Read more →ACIUAC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
AC Immune has initiated the final cohort in its Phase 1b/2 ABATE trial for ACI-24, an anti-Abeta immunotherapy for Alzheimer's disease. The first patient in Cohort AD4 has been treated, triggering a $12 million milestone payment from Takeda. Results from earlier cohorts are expected in Q2 2026, with promising early data on safety and immunogenicity.
Read more →ACIUAC Immune Initiates Final Cohort in Ongoing Phase Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
AC Immune SA has announced the initiation of the final cohort, AD4, in its ongoing Phase 1b/2 ABATE trial of the anti-Abeta immunotherapy ACI-24 for Alzheimer's disease. The dosing of the first patients in this cohort triggers a $12 million milestone payment from Takeda, which is collaborating on this project. Preliminary data indicates that ACI-24 is generally safe and has induced positive antibody responses against amyloid beta, a key factor in Alzheimer's pathology. The trial aims to expand on these findings with a total of 36 subjects treated for 12 months, followed by a potential cohort expansion to 112 participants.
Read more →ACIU▲ +15.2%on this news
AC Immune Announces Amendment to Morphomer Tau License And Collaboration Agreement With Lilly
AC Immune Announces Amendment to Morphomer Tau License And Collaboration Agreement With Lilly
Read more →ACIU▲ +15.2%on this news
AC Immune Announces Amendment to Morphomer Tau License and Collaboration Agreement with Lilly
AC Immune SA has amended its 2018 collaboration agreement with Eli Lilly to enhance research on Tau aggregation inhibitors for Alzheimer's and other neurodegenerative diseases. The agreement includes a CHF10 million upfront payment and eligibility for over CHF1.7 billion in milestone payments. AC Immune's CEO highlighted the potential of their Morphomer small molecules to target intracellular Tau. Furthermore, promising preclinical data supports the clinical relevance of these candidates in inhibiting Tau aggregation.
Read more →ACIUAC Immune Presents First in Vivo Images of Brain TDP 43 Pathology From Phase 1 Trial of PET Tracer ACI 19626 at AD Pdtm 2026
AC Immune Presents First in Vivo Images of Brain TDP 43 Pathology From Phase 1 Trial of PET Tracer ACI 19626 at AD Pdtm 2026
Read more →ACIUAC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
AC Immune SA reported its financial results for 2025, highlighting promising Phase 2 interim results for ACI-7104, which may slow Parkinson's disease progression. The company initiated a Phase 1 trial for ACI-19764, a NLRP3 inhibitor. Despite a cash position of CHF 91.4 million, the company reported a net loss of CHF 70.5 million and a significant drop in contract revenues compared to the previous year.
Read more →About AC Immune SA
HeadquartersLausanne
Founded2003
BIOPHARMAWATCH ELITE PLUS
Trade the next ACIU catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime